Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3540378 in worsening HFpEF
NCT05592275Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of volenrelaxin in heart failure with preserved ejection fraction (HFpEF), sponsored by Eli Lilly and Company. Started Feb 2023; status: terminated.
02
Drugs
volenrelaxin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05592275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592275.